In addition, management may also discuss non-GAAP operating performance results during today's call, including earnings before interest, taxes, depreciation, and amortization or EBITDA and adjusted EBITDA. Roto-Rooter revenue increased 1.1% in the third quarter of 2025 compared to the same period of 2024. Branch residential and commercial revenue were both encouraging, with increases of 3.4% and 2.8% respectively. Revenue from independent contractors continues to be disappointing, declining 4.7% in the third quarter of 2025.

For the first time in several quarters, we saw strength in our residential plumbing revenue service line. Residential plumbing revenue increased 8.2% in the third quarter of 2025 compared to the same period of 2024. A multi-pronged campaign to target selected high-revenue dollar plumbing services yielded positive results in the quarter. While we are paying for more leads, causing some margin pressure, we also believe this trend indicates a potential moderation of competition for leads from our most significant private equity competitors.

However, gross margin during the quarter was exactly in line with our guidance. The shift from unpaid leads to paid leads was the main driver of the $3.6 million increase in SG&A costs in the quarter. This led to EBITDA and EBITDA margins to be slightly lower than our expectations for the quarter. While still below our long-term expectations, there are signs that the Roto-Rooter business has stabilized and is on the way to returning to a predictable, sustainable growth trajectory.

What went well
  • Both operating units performed primarily in line with expectations in the third quarter of 2025.
  • VITAS admissions totaled 17,714, a 5.6% improvement over the prior year, with average daily census up 2.5% to 22,327 patients and net revenue up 4.2% to $407.7 million.
  • The strategy to admit a higher percentage of hospital-based patients gained traction, with the hospital admissions ratio reaching 44.5% (a post-pandemic high watermark within the preferred 42%-45% range), supporting management's belief that there will be no Florida Medicare cap billing limitation in 2026.
  • The 2025 Florida billing limitation came in slightly better than estimated at $18.9 million versus a projected $19 million.
  • At Roto-Rooter, residential plumbing revenue rose 8.2% for the first time showing strength in several quarters, total leads improved (down only 1.3%), and sequential EBITDA margin improved about 90 basis points.
  • Management reiterated full-year guidance of $22.00-$22.30 per share and indicated it is shooting for the upper end.
What went wrong
  • VITAS adjusted EBITDA excluding Medicare cap declined 3.8% to $70.4 million, with margin of 17.0% down 157 basis points year over year, reflecting the impact of admitting more lower-margin hospital-based short-stay patients.
  • A $6.1 million Medicare cap billing limitation was accrued in the quarter ($4.6 million Florida, $1.5 million mainly California).
  • Roto-Rooter adjusted EBITDA fell 12.4% to $49.4 million with margin of 22.7%, a 351 basis point year-over-year decline, as a shift from natural to paid leads drove a $3.6 million increase in SG&A; revenue from independent contractors declined 4.7% and remains disappointing.
  • Roto-Rooter margins remain below long-term expectations, and DSO was somewhat elevated due to slower Medicaid payment timing.

Guidance Changes

MetricPeriodCurrent guidance
Full-year EPSFY2025$22.00-$22.30 (Reiterated (targeting upper end))
VITAS revenue growthFY2026~8% range (preliminary) (New / speculative)
VITAS EBITDA marginFY2026~17.5%-18% (preliminary) (New / speculative)
Roto-Rooter revenue growthFY2026~3%-5% (preliminary budget range) (New / speculative)

Performance Breakdown

MetricYoYNote
VITAS net revenue +4.2% 2.5% increase in days of care and ~4.1% weighted average Medicare reimbursement rate increase, partly offset by acuity mix and Medicare cap/contra-revenue
VITAS adjusted EBITDA (ex-cap) -3.8% Impact of admitting more hospital-based short-stay patients lowering margin to 17.0%
VITAS average daily census +2.5% Census growth to 22,327 patients
Roto-Rooter revenue +1.1% Branch residential (+3.4%) and commercial (+2.8%) growth offset by independent contractor revenue decline of 4.7%
Roto-Rooter adjusted EBITDA -12.4% $3.6M SG&A increase from shift to paid leads pressuring margin to 22.7%
Roto-Rooter residential plumbing revenue +8.2% Multi-pronged campaign targeting high-revenue plumbing services

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
Florida Medicare cap mitigationEstimated $19M 2025 Florida billing limitation; ratio dipped below preferred range during community access program$18.9M actual 2025 limitation; hospital admission ratio back to 44.5%; management expects no Florida cap in 2026Improving
Roto-Rooter lead generation shiftIncreasing paid leads offsetting declining natural leads discussed prior two quartersPaid leads up 8.6%, total leads down only 1.3%; signals moderation of private equity competitionImproving
Roto-Rooter margin recoveryBelow long-term expectations; multi-quarter fix acknowledged in Q2Sequential margin up ~90 bps; long-term target 25%-26% EBITDA margin; pricing discipline tied to higher lead volumeRecovering
VITAS length of stay normalizationQ2 2025 average length of stay 137.1 days; community access created bubble of long-stay patientsQ3 average length of stay 109.7 days, median 18 days, returning to normal as hospital pre-admit focus increasesNormalizing

Q&A Summary

What bridges results back to guidance in the fourth quarter for each segment?
Witzeman cited seasonality: VITAS Q4 is its best quarter due to the October 1 rate increase against an unchanged cost structure, and Roto-Rooter does better in Q4 and Q1 on weather; he expected only a couple million dollars difference between quarters and continued Roto-Rooter margin improvement.
How are you thinking about the 2026 growth algorithm for VITAS?
Witzeman said it is early in budgeting and Q4 Florida cap results will inform strategy, but off the top of his head revenue around 8% and margins in the 17.5%-18% range, with the ability to creep back to longer-stay patients if the Q4 cap liability is moderate.
Can you discuss improving competitive dynamics in Roto-Rooter and SG&A opportunity?
Witzeman and McNamara explained paid leads were up high single digits while only unpaid leads declined, with competitors (including private equity) all forced to pay more for leads; getting enough jobs on the board improves pricing discipline and margin.
What are sustainable Roto-Rooter margins given higher marketing costs?
Witzeman said the right long-term EBITDA margin is 25%-26%, not yet reached; higher marketing costs can be absorbed by higher leads and revenue, with continued near-term pressure offset by operational improvements.
Why do you assume no Florida cap liability in 2026?
Wherley said it is driven by the hospital pre-admit strategy (44.5% ratio in the preferred range) and the Pinellas opening, not just the smaller rate increase; Witzeman noted the Florida rate delta is now a $3-$4 million headwind versus $22-$25 million last year.
What drove the larger-than-historical sequential VITAS gross margin improvement?
Witzeman said nothing specific, attributing it to efficiency efforts and managing costs program by program, including proper staffing adjustments in Florida, with SG&A down year over year.

More on Chemed Corp

Reported 2025-10-29 · figures from the Chemed Corp Q3 2025 earnings call.

See how VectorShift works for your firm

Request Demo